Initial Data from Allarity's Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical ... | Region
Boston, MA (July 5, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for